Read by QxMD icon Read

olivera pável

Pável Olivera, Miren Gabilondo, Mireia Constans, Dolors Tàssies, Esther Plensa, Verónica Pons, Germán Las Heras, Carmen Jiménez, Desirée Campoy, Anna Bustins, Artur Oliver, Cristina Marzo, Tania Canals, Anna Varela, Marc Sorigue, Eva Sánchez, Gabriela Ene, Granada Perea, Laura Vicente, Meritxell López, María Cerdá, Erik Johansson, M Reyes Aguinaco, Nazly Santos, José Mateo, Joan Carles Reverter, Ángel Moya, Amparo Santamaría
BACKGROUND AND OBJECTIVES: In recent years, direct oral anticoagulants (DOACs) have become an alternative to vitamin K antagonists (VKA) for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) as well as for prevention and treatment of deep venous thrombosis. Pivotal trials have demonstrated non-inferiority and potential superiority compared to warfarin, which increases the options of anticoagulant treatment. In our setting, the Anticoagulant Treatment Units (ATUs) and Primary Care Centres (PCCs) play an important role in the education, follow-up, adherence control and management in special situations of anticoagulated patients...
March 27, 2018: Medicina Clínica
Tomás José González-López, Fernando Fernández-Fuertes, José Angel Hernández-Rivas, Blanca Sánchez-González, Violeta Martínez-Robles, María Teresa Alvarez-Román, Gloria Pérez-Rus, Cristina Pascual, Silvia Bernat, Esther Arrieta-Cerdán, Carlos Aguilar, Abelardo Bárez, María Jesús Peñarrubia, Pavel Olivera, Angeles Fernández-Rodríguez, Erik de Cabo, Luis Javier García-Frade, José Ramón González-Porras
Eltrombopag is safe and effective in primary chronic ITP. However, lack of clinical trials avoids a clear demonstration of its utility in newly diagnosed and persistent ITP. Our aim here is to report Spanish results for this type of patients. We retrospectively evaluated 220 adult primary ITP patients. According to standard definition, patients were allocated to newly diagnosed (n = 30), persistent (n = 30), and chronic (n = 160) ITP. Groups were homogenous regarding most relevant parameters. 180 (90%) of 220 patients achieved a platelet response (R) with 167 (75...
October 2017: International Journal of Hematology
Tomás J González-López, María T Alvarez-Román, Cristina Pascual, Blanca Sánchez-González, Fernando Fernández-Fuentes, Gloria Pérez-Rus, José A Hernández-Rivas, Silvia Bernat, José M Bastida, María P Martínez-Badas, Violeta Martínez-Robles, Inmaculada Soto, Pavel Olivera, Estefanía Bolaños, Rafael Alonso, Laura Entrena, Marta Gómez-Nuñez, Arancha Alonso, María Yera Cobo, Isabel Caparrós, María Tenorio, Esther Arrieta-Cerdán, Elsa Lopez-Ansoar, Javier García-Frade, José R González-Porras
Eltrombopag is a second-line treatment in primary immune thrombocytopenia (ITP). However, its role in secondary ITP is unknown. We evaluated the efficacy and safety of eltrombopag in secondary ITP in daily clinical practice. Eighty-seven secondary ITP patients (46 with ITP secondary to autoimmune syndromes, 23 with ITP secondary to a neoplastic disease subtype: lymphoproliferative disorders [LPDs] and 18 with ITP secondary to viral infections) who had been treated with eltrombopag were retrospectively evaluated...
September 2017: British Journal of Haematology
Tomás José González-López, María Teresa Alvarez-Román, Cristina Pascual, Blanca Sánchez-González, Fernando Fernández-Fuentes, Isidro Jarque, Gloria Pérez-Rus, Susana Pérez-Crespo, Silvia Bernat, José Angel Hernández-Rivas, Marcio M Andrade, Montserrat Cortés, Marta Gómez-Nuñez, Pavel Olivera, Violeta Martínez-Robles, Angeles Fernández-Rodríguez, Miguel Angel Fuertes-Palacio, Carmen Fernández-Miñano, Erik de Cabo, Rosa Fisac, Carlos Aguilar, Abelardo Bárez, María Jesús Peñarrubia, Luis Javier García-Frade, José Ramón González-Porras
BACKGROUND: Eltrombopag is effective and safe in chronic immune thrombocytopenia (ITP). However, clinical trials may not accurately reflect what happens in clinical practice. We evaluated the efficacy and safety of eltrombopag in primary chronic ITP in a real-world setting. METHODS: A total of 164 primary patients with chronic ITP from 40 Spanish centers, who had been treated with eltrombopag, were retrospectively evaluated. RESULTS: The median age of our cohort (72% women) was 63 yr (interquartile range, IQR, 45-75 yr)...
September 2016: European Journal of Haematology
Verónica Pons, Pável Olivera, Roberto García-Consuegra, Laura López-Andreoni, Nieves Martín-Begué, Angel García, Juliana Hidalgo, Francesc Bosch, Amparo Santamaría
Congenital plasminogen deficiency is a rare autosomal recessive disorder, characterized by chronic mucosal membranous lesions. Although the most common clinical manifestation is eye involvement as ligneous conjunctivitis, extra-ocular lesions affecting other mucosal surfaces indicates a systemic disease. In this report we describe two cases with atypical extra-ocular involvement that includes pericarditis and recurrent hematocolpos, and one with paradoxical correlation between ocular lesions and plasminogen levels...
April 2016: Journal of Thrombosis and Thrombolysis
José Ramón González-Porras, María Eva Mingot-Castellano, Marcio M Andrade, Rafael Alonso, Isabel Caparrós, María Carmen Arratibel, Fernando Fernández-Fuertes, Maria José Cortti, Cristina Pascual, Blanca Sánchez-González, Silvia Bernat, Miguel Angel Fuertes-Palacio, Juan Andrés Vázquez-Paganini, Pavel E Olivera, María Teresa Alvarez-Román, Isidro Jarque, Montserrat Cortés, Violeta Martínez-Robles, Francisco Javier Díaz-Gálvez, María Calbacho, Carmen Fernández-Miñano, Javier Garcia-Frade, Tomás José González-López
The thrombopoietin receptor agonists (THPO-RAs), romiplostim and eltrombopag, are effective and safe in immune thrombocytopenia (ITP). However, the value of their sequential use when no response is achieved or when adverse events occur with one THPO-RA has not been clearly established. Here we retrospectively evaluated 51 primary ITP adult patients treated with romiplostim followed by eltrombopag. The median age of our cohort was 49 (range, 18-83) years. There were 32 women and 19 men. The median duration of romiplostim use before switching to eltrombopag was 12 (interquartile range 5-21) months...
April 2015: British Journal of Haematology
Tomás José González-López, Cristina Pascual, María Teresa Álvarez-Román, Fernando Fernández-Fuertes, Blanca Sánchez-González, Isabel Caparrós, Isidro Jarque, María Eva Mingot-Castellano, José Angel Hernández-Rivas, Mónica Martín-Salces, Laura Solán, Paola Beneit, Reyes Jiménez, Silvia Bernat, Marcio M Andrade, Montserrat Cortés, Maria José Cortti, Susana Pérez-Crespo, Marta Gómez-Núñez, Pavel E Olivera, Gloria Pérez-Rus, Violeta Martínez-Robles, Rafael Alonso, Angeles Fernández-Rodríguez, María Carmen Arratibel, María Perera, Carmen Fernández-Miñano, Miguel Angel Fuertes-Palacio, Juan Andrés Vázquez-Paganini, Isabel Gutierrez-Jomarrón, Inés Valcarce, Erik de Cabo, Adriana Sainz, Rosa Fisac, Carlos Aguilar, María Paz Martínez-Badas, María Jesús Peñarrubia, María Calbacho, Carmen de Cos, Manuel González-Silva, Erika Coria, Arancha Alonso, Alberto Casaus, Armando Luaña, Pilar Galán, Cristina Fernández-Canal, Javier Garcia-Frade, José Ramón González-Porras
Eltrombopag is effective and safe in immune thrombocytopenia (ITP). Some patients may sustain their platelet response when treatment is withdrawn but the frequency of this phenomenon is unknown. We retrospectively evaluated 260 adult primary ITP patients (165 women and 95 men; median age, 62 years) treated with eltrombopag after a median time from diagnosis of 24 months. Among the 201 patients who achieved a complete remission (platelet count >100 × 10(9) /l), eltrombopag was discontinued in 80 patients...
March 2015: American Journal of Hematology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"